Friday, May 9, 2025
5/9/2025
Targeting TGF-beta activation in tumors - Targeting TGF-b activation in tumors Abstract Transforming growth factor-ß (TGF-ß) drives immune dysfunction in the tumor microenvironment by inducing regulatory T cells (Tregs) and inhibiting cytolytic CD8+ T cells and helper Th1 cells. TGF-b is ubiquitously expressed in mammals as isoforms TGF-b1, -b2, and -b3, but is maintained in an inactive form by non-covalent interaction with its propeptide, the latency associated domain of TGF-b (LAP). The integrin avb8 binds to the LAP of TGF-b1 and TGF-b3 and mediates their activation. Germline or conditional genetic deletion studies have revealed that integrin avb8-mediated activation of TGF-b is essential for the in vivo activation of TGF-b, and thus avb8 acts as a key modulator of TGF-b function. In general, integrins are adhesion molecules and mediate the attachment of cells to extracellular matrix proteins. Integrin avb8 recognizes an Arg-Gly-Asp (RGD) motif and interacts with fibronectin, vitronectin, and latent TGF-ß isoforms, although it binds considerably more strongly to latent TGF-ß than to other RGD-containing proteins (Ozawa, 2016). Despite the clear association of TGF-b signaling and T cell function, few therapies that target TGF-b have been successful, largely due to pan-inhibitor toxicity. To address this therapeutic challenge, we have identified a mouse monoclonal antibody (AMHA-11) that selectively blocks the interaction of the human integrin avb8 with its ligand, latent transforming growth factor-b (TGF-b). The AMHA-11 antibody is unique in that it selectively perturbs the avb8-mediated activation of TGF-b isoforms 1 and 3 and does not inhibit TGF-b2, which lacks an integrin-binding RGD motif. Additionally, because of redundant activities of other av integrins, cell adhesion is not perturbed by AMHA-11. This affords a higher degree of selectivity in perturbing only integrin avb8-mediated activation of TGF-b activation and not the residual cell adhesion properties, which may be undesirable to inhibit. In addition, global inactivation of TGF-b is likely to have undesirable side effects since TGF-b is an essential homeostatic epithelial and immune effector. In Phase 1 we will identify high-affinity humAbs that inhibit avb8-mediated activation of TGF-b, then rank-order them in vitro for their ability to inhibit TGF-b activation and to modulate T cell activity. We will also evaluate them in a small animal model as monotherapy and in combination with anti-PD-1. We are confident that a novel therapy will result from this more selective approach.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).